RxDoctor Payments Data

Shama Zakai, MD

Internal Medicine · Bronx, NYNPI 1780216903

Payments from drug & device makers

$11,539in general payments, 2019–2025

Across 300 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • Neurocrine Biosciences, Inc.$2K
  • Gilead$2K
  • AstraZeneca$2K
  • Viiv Healthcare Company$862
  • EMD Serono, Inc.$711
  • plus $996 from 5 others

What the payments were for

  • Food & beverage$11,33298%
  • Education$2072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,539 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$335,116
Medicare patients
115
Services billed
3,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine162$439,468
IngrezzaValbenazine Tosylate78$234,814
EliquisApixaban525$155,692
BiktarvyBictegrav/Emtricit/Tenofov Ala31$130,633
Tetrabenazine105$92,937
XifaxanRifaximin43$68,970
OdefseyEmtricitab/Rilpiviri/Tenof Ala15$57,980
TivicayDolutegravir Sodium32$40,526
TrulicityDulaglutide38$36,228
JardianceEmpagliflozin70$21,194
JanuviaSitagliptin Phosphate71$21,039
AbrysvoRsv Vacc, Pref A And Pref B/Pf65$20,462
XareltoRivaroxaban66$18,997
EntrestoSacubitril/Valsartan51$18,706
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam57$14,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$3,187$439,468162 claims
Neurocrine Biosciences, Inc.Ingrezza$2,150$234,81478 claims
GileadBiktarvy$1,958$130,63331 claims
Viiv Healthcare CompanyTivicay$862$40,52632 claims
Lilly USA, LLCTrulicity$126$36,22838 claims
Johnson & JohnsonXarelto$114$18,99766 claims
AstraZenecaFarxiga, Lokelma$1,676$13,25644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →